VIRX (Viracta Therapeutics) OCF Margin %: 0.00% (As of Sep. 2024)


What is Viracta Therapeutics OCF Margin %?

Viracta Therapeutics VIRX OCF Margin % is 0.00% as of Sep. 2024.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Viracta Therapeutics's Cash Flow from Operations for the three months ended in Sep. 2024 was $-7.09 Mil. Viracta Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Viracta Therapeutics's OCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Viracta Therapeutics's current OCF Yield % is -8,944.99%.

The historical rank and industry rank for Viracta Therapeutics's OCF Margin % or its related term are showing as below:


VIRX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Viracta Therapeutics OCF Margin % Related Terms

Viracta Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics OCF Margin % Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
OCF Margin %
0.00 0.00 0.00 0.00

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viracta Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Viracta Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-39.892/0
= %

Viracta Therapeutics's OCF Margin for the quarter that ended in Sep. 2024 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-7.093/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Viracta Therapeutics (VIRX) has a OCF Margin % of 0.00% as of Sep. 2024. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' OCF Margin % too high?
Viracta Therapeutics' current OCF Margin % is 0.00%.
How does Viracta Therapeutics' OCF Margin % compare to TSOI and CYTOF?
Viracta Therapeutics' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current OCF Margin % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.